Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

August 12, 2025

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

News Daily News

Trade-offs With Invasive Strategy in Older Patients With ACS: Meta-analysis

Michael O'Riordan

July 03, 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.